# A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers

> **NCT01400646** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 46 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Rivaroxaban
- **DRUG:** Warfarin
- **DRUG:** Vitamin K
- **DRUG:** Vitamin K
- **DRUG:** Warfarin
- **DRUG:** Warfarin
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT01400646
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2017-01-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01400646

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01400646, "A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01400646. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*